Pulmonary Fibrosis Therapeutics Pipeline H2 2014 Review Market Research Report

News provided by

Jan 21, 2015, 01:00 ET

DALLAS, January 21, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Pulmonary Fibrosis - Pipeline Review, H2 2014" market research report to its store. This report provides an overview of the Pulmonary Fibrosis's therapeutic pipeline.

The report "Pulmonary Fibrosis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects.

Pulmonary fibrosis occurs when lung tissue becomes damaged and scarred. In some patients the specific cause of the disease can be diagnosed, but in others the probable cause cannot be determined, a condition called idiopathic pulmonary fibrosis. There is no known cure for the scars and damage in the lung due to pulmonary fibrosis. Symptoms of pulmonary fibrosis are mainly: Shortness of breath, Chronic dry, hacking coughing, Fatigue and weakness, Chest discomfort including chest pain, Loss of appetite and rapid weight loss.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=256234 . (This is a premium report priced at US$2000 for a single user License.)

Companies discussed in this Pulmonary Fibrosis - Pipeline Review, H2 2014 report include AdAlta Pty Ltd., Aeolus Pharmaceuticals, Inc., AnaptysBio, Inc., Angion Biomedica Corp., Aquinox Pharmaceuticals Inc., Auspex Pharmaceuticals, Inc., Biogen Idec Inc., BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Carolus Therapeutics, Inc., Celgene Corporation, Chong Kun Dang Pharmaceutical Corp., Compugen Ltd., Corridor Pharmaceuticals Inc., Digna Biotech, S.L., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Five Prime Therapeutics, Inc., Galectin Therapeutics, Inc., GenKyoTex S.A., Gilead Sciences, Inc., GlaxoSmithKline plc, HanAll Biopharma Co., Ltd., Histocell S.L., iBio, Inc., IMMD Inc., ImmuneWorks, LLC, IntelGenx Corp., InterMune, Inc., Inventiva SAS, Kasiak Research Pvt. Ltd., Kyorin Pharmaceutical Co., Ltd., Lanthio Pharma B.V., Lpath, Inc., LTT Bio-Pharma Co., Ltd., MedImmune, LLC, Mesoblast Limited, miRagen Therapeutics, Inc., Moerae Matrix, Inc., MSM Protein Technologies, Inc., NicOx S.A., Pacific Therapeutics Ltd., Pharmaxis Limited, Pluristem Therapeutics Inc., Progenra, Inc., Promedior, Inc., ProMetic Life Sciences Inc., Pulmatrix, Inc., RestorGenex Corporation, Rhizen Pharmaceuticals SA, Sanofi, Therametrics holding AG, Vectura Group plc.

Scope of Pulmonary Fibrosis - Pipeline Review, H2 2014 covers: a snapshot of the global therapeutic landscape of Pulmonary Fibrosis; reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; reviews key players involved in the therapeutics development for Pulmonary Fibrosis and enlists all their major and minor projects; summarizes all the dormant and discontinued pipeline projects; review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Pulmonary Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type as well as Latest news and deals relating related to pipeline products.

Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=256234 . (This is a premium report priced at US$2000 for a single user License.)

Global Markets Direct report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Pulmonary Fibrosis
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Respiratory therapeutics athttp://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/respiratory-therapeutics .

Emphysema - Pipeline Review, H2 2014

This report provides comprehensive information on the therapeutic development for Emphysema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Emphysema and special features on late-stage and discontinued projects.

A similar report is also available on Diphtheria - Pipeline Review, H2 2014 at http://www.rnrmarketresearch.com/diphtheria-pipeline-review-h2-2014-market-report.html .

About Us:
RnRMarketResearch.com is a digital library of 500,000+ syndicated market research reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.

Contact:

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441

[email protected]

Connect with Us:

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research